A first-in-human, Phase I/II trial of ST-101 for the treatment of advanced hematologic malignancies
Latest Information Update: 10 Sep 2019
At a glance
- Drugs Lucicebtide (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions; First in man; Therapeutic Use
- 10 Sep 2019 New trial record
- 04 Sep 2019 According to a Sapience Therapeutics media release, the compay expects to initiate this trial in first half of 2020.